In vitro fertilization outcome in women with diminished ovarian reserve
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: This study aimed to identify factors that affect in vitro fertilization (IVF) outcomes in women with diminished ovarian reserve (DOR). Methods: We reviewed 99 IVF cycles in 52 women with DOR between September 2010 and January 2015. DOR was defined as serum anti-Müllerian hormone level of <1.1 ng/dL or serum follicle-stimulating hormone level of ≥20 mIU/mL. Total 96 cycles in 50 patients were evaluated after excluding fertility preservation cases. Results: The clinical pregnancy rate was 11.5% per cycle, and the total cancellation rate was 34.4%. Clinical pregnancy rate was significantly associated with the antral follicle count and the cause of the DOR. Age, serum anti-Müllerian hormone and follicle-stimulating hormone levels, antral follicle count, peak estradiol level, and the cause of DOR were significantly associated with cycle cancellation. However, history of previous ovarian surgery remained as a significant factor of clinical pregnancy (model 1: odds ratio [OR] 10.17, 95% confidence interval [CI] 1.46 to 70.84, P=0.019; model 2: OR 10.85, 95% CI 1.05 to 111.71, P=0.045). In cancellation models, idiopathic or previous chemotherapy group showed borderline significance (model 1: OR 3.76, 95% CI 0.83 to 17.04, P=0.086; model 2: OR 3.15, 95% CI 0.84 to 11.84, P=0.09). Conclusion: DOR caused by previous ovarian surgery may show better pregnancy outcome, whereas that caused by chemotherapy could significantly increase the cycle cancellation rate. Furthermore, patients with DOR who previously received gonadotoxic agents may show reduced efficacy and increased risk of IVF cycle cancellation.
Abstract
Objective: This study aimed to identify factors that affect in vitro fertilization (IVF) outcomes in women with diminished ovarian reserve (DOR). Methods: We reviewed 99 IVF cycles in 52 women with DOR between September 2010 and January 2015. DOR was defined as serum anti-Müllerian hormone level of <1.1 ng/dL or serum follicle-stimulating hormone level of ≥20 mIU/mL. Total 96 cycles in 50 patients were evaluated after excluding fertility preservation cases. Results: The clinical pregnancy rate was 11.5% per cycle, and the total cancellation rate was 34.4%. Clinical pregnancy rate was significantly associated with the antral follicle count and the cause of the DOR. Age, serum anti-Müllerian hormone and follicle-stimulating hormone levels, antral follicle count, peak estradiol level, and the cause of DOR were significantly associated with cycle cancellation. However, history of previous ovarian surgery remained as a significant factor of clinical pregnancy (model 1: odds ratio [OR] 10.17, 95% confidence interval [CI] 1.46 to 70.84, P=0.019; model 2: OR 10.85, 95% CI 1.05 to 111.71, P=0.045). In cancellation models, idiopathic or previous chemotherapy group showed borderline significance (model 1: OR 3.76, 95% CI 0.83 to 17.04, P=0.086; model 2: OR 3.15, 95% CI 0.84 to 11.84, P=0.09). Conclusion: DOR caused by previous ovarian surgery may show better pregnancy outcome, whereas that caused by chemotherapy could significantly increase the cycle cancellation rate. Furthermore, patients with DOR who previously received gonadotoxic agents may show reduced efficacy and increased risk of IVF cycle cancellation.
참고문헌 (10)
- Cohen J, "Diminished ovarian reserve, premature ovarian failure, poor ovarian responder:a plea for universal definitions", J Assist Reprod Genet, 32, pp.1709~1712 (2015)
- Ferraretti AP, "ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria", Hum Reprod, 26, pp.1616~1624 (2011)
- Roustan A, "Surgical diminished ovarian reserve after endometrioma cystectomy versus idiopathic DOR: comparison of in vitro fertilization outcome", Hum Reprod, 30, pp.840~847 (2015)
- Bonilla-Musoles F, "Predicting ovarian reserve and reproductive outcome using antimullerian hormone (AMH) and antral follicle count (AFC) in patients with previous assisted reproduction technique (ART) failure", Clin Exp Obstet Gynecol, 39, pp.13~18 (2012)
- Brodin T, "Antimullerian hormone levels are strongly associated with live-birth rates after assisted reproduction", J Clin Endocrinol Metab, 98, pp.1107~1114 (2013)
- Reijnders IF, "The value of Anti-Müllerian hormone in low and extremely low ovarian reserve in relation to live birth after in vitro fertilization", Eur J Obstet Gynecol Reprod Biol, 200, pp.45~50 (2016)
- El-Toukhy T, "Young age does not protect against the adverse effects of reduced ovarian reserve: an eight year study", Hum Reprod, 17, pp.1519~1524 (2002)
- Gonzalez-Foruria I, "Age, independent from ovarian reserve status, is the main prognostic factor in natural cycle in vitro fertilization", Fertil Steril, 106, pp.342-7.e2~ (2016)
- Das M, "Ovarian reserve and response to IVF and in vitro maturation treatment following chemotherapy", Hum Reprod, 27, pp.2509~2514 (2012)
- Chan JL, "Outcomes of ovarian stimulation after treatment with chemotherapy", J Assist Reprod Genet, 32, pp.1537~1545 (2015)